Weisel, Katja http://orcid.org/0000-0001-9422-6614
Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
Gay, Francesca
Delforge, Michel
Cook, Gordon http://orcid.org/0000-0003-1717-0412
Szabo, Zsolt
Desgraz, Renaud
DeCosta, Lucy
Moreau, Philippe
Funding for this research was provided by:
Amgen (Europe) GmbH
Article History
Received: 5 May 2020
Revised: 30 July 2020
Accepted: 29 September 2020
First Online: 16 October 2020
Compliance with ethical standards
:
: KW has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen and Takeda; served in a consulting role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Juno, Sanofi and Takeda; and received research funding from Amgen, Celgene, Janssen and Sanofi. M-VM has received honoraria from Amgen, Celgene, Janssen and Takeda for lectures and participation in advisory boards. FG has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen and Takeda; and served as an advisor for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Roche, Oncopeptides, Abbvie, Adaptive, and Takeda. MD has received honoraria from Amgen, Celgene, Janssen and Takeda for consultancy and advisory boards; and research honoraria from Celgene and Janssen. GC has received research funding and honoraria from Celgene, Janssen and Takeda; and honoraria from Amgen, Bristol-Myers Squibb, GlycoMimetics and Sanofi. ZS is an employee of Amgen (Europe) GmbH and holds Amgen stocks. RD is an employee of Amgen (Europe) GmbH and holds Amgen stocks. LD is an employee of Amgen Ltd and holds Amgen stocks. PM has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Novartis, Onyx Pharmaceuticals and Takeda; and served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Novartis, Onyx Pharmaceuticals and Takeda.